Crestline Management’s Vaxcyte PCVX Stock Holding History

Crestline Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-101,035	Closed	-$8.27M	–	468
2024 Q4	$8.27M	Buy	101,035 +47,452	+89%	+$4.71M	0.28%	71
2024 Q3	$6.12M	Buy	+53,583	New	+$4.83M	0.32%	88
2020 Q3	–	Sell	-7,000	Closed	-$221K	–	172
2020 Q2	$221K	Buy	+7,000	New	+$225K	0.04%	135

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Crestline Management's PCVX Position: Q1 2025 in Review

Crestline Management sold out of Vaxcyte (PCVX) in Q1 2025, closing a stake of 101,035 shares — an estimated $8.27M sold.

Crestline Management first reported a position in PCVX in Q2 2020 and held it in 3 quarters. The position peaked at $8.27M in Q4 2024. 315 funds tracked by Wall St. Rank hold PCVX as of Q1 2025.

Crestline Management reported no remaining Vaxcyte position as of Q1 2025 after selling out during the quarter.
Crestline Management sold 101,035 Vaxcyte shares in Q1 2025, an estimated $8.27M.
Crestline Management first reported a position in Vaxcyte in Q2 2020 and held it in 3 quarters.
Crestline Management's Vaxcyte position peaked at $8.27M in Q4 2024.
315 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.